BMO Capital Reiterates Outperform Rating on Biogen (BIIB)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- S&P, Dow edge higher on Mideast deal hopes; SpaceX debut in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil falls to near two-month lows as Trump calls off threatened strikes on Iran
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
Leqembi® (lecanemab) Authorized for Early Alzheimer's Disease in Great Britain
August 22, 2024 5:11 AM EDTFOR GLOBAL MEDIA AND JOURNALISTS OUTSIDE THE EMEA REGIONÂ
In Great Britain, lecanemab is indicated for the treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease (AD) in adult patients that are apolipoprotein E 4 (ApoE 4)* heterozygotes or non-carriers1
Great Britain becomes the first country in Europe to authorize the medicine, which targets an underlying cause of... More
